| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 32.20 | 0.00 (0.00%) | 21.05 - 39.00 | 5.8 thousand (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse
06/10/2013 9:00 AM ET
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
06/02/2013 9:00 AM ET